Announcements Trials
Browse Landscape

Status

Completed 7Recruiting 6Active not recruiting 4Unknown 2

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 48Observational 7

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 6DILI 1

Interventions

Surveys and Questionnaires 286Blood Specimen Collection 145Gene Expression Profiling 96Interviews as Topic 83Immunohistochemistry 78Polymerase Chain Reaction 64Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 58Microarray Analysis 55Flow Cytometry 53Radiotherapy 49Amplified Fragment Length Polymorphism Analysis 48Drug Therapy 46Observation 45Biopsy 42Reverse Transcriptase Polymerase Chain Reaction 39Bevacizumab 39Data Collection 35Sorafenib 29Psychiatric Rehabilitation 29Nivolumab 28palbociclib 26In Situ Hybridization, Fluorescence 26Rituximab 25Therapeutics 24Neoadjuvant Therapy 24Hepatectomy 24Docetaxel 24Colonoscopy 24Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Completed × Observational × ribociclib × Clear all
NCT06075758 2026-05-06

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

Novartis

Completed
175 enrolled
Breast

Breast Neoplasms

NCT04943497 2026-04-01

PROSPERITY

Novartis

Completed
2,424 enrolled
Breast

Breast Neoplasms

NCT07072013 2025-07-18

IRINA

Novartis

Completed
1,937 enrolled
Breast

Breast Neoplasms

NCT03956654 2024-08-09

RibOB

Universitaire Ziekenhuizen KU Leuven

Completed
78 enrolled
Breast

Breast Neoplasms

NCT06367335 2024-04-16

ETIC

University of Milano Bicocca

Completed
128 enrolled

DILI

NCT05569187 2022-11-08

Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

Novartis

Completed
76 enrolled
Breast

Breast Neoplasms

NCT05153135 2021-12-21

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Novartis

Completed
4,320 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡